A Phase 2/3 interventional study of risankizumab IV and placebo for risankizumab in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 430 sites in 44 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-16.
Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Colitis, Ulcerative by AbbVie — 6 open to participants now, 13 under way, 5 of them phase 3. Colitis, Ulcerative · AbbVie.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2/3, and was the 27th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →6 of the 53 studies in Colitis, Ulcerative by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
AbbVie · Sites in Japan
Ages 15+
AbbVie · Sites in United States, Belgium, Brazil and 13 more countries
Ages 2–17
AbbVie · Sites in China
Ages 18+
AbbVie · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 21 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,558 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 156 across the 31 interventional studies, 200 across the 20 observational. Of the 36 that completed or were terminated, 22 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
5 of the studies in Colitis, Ulcerative by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT06838845AbbVieAn Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | 2026-12 |
| NCT05496348AbbVieStudy of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | 2027-08 |
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies in Colitis, Ulcerative by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2.
The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
Drug: placebo for risankizumab
Participants randomized to receive risankizumab 600mg administered by intravenous (IV) infusion.
Drug: risankizumab IV
Participants randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion.
Drug: risankizumab IV
Participants randomized to receive risankizumab 1800mg administered by intravenous (IV) infusion.
Drug: risankizumab IV
Participants receive risankizumab 1800mg administered by intravenous (IV) infusion.
Drug: risankizumab IV
Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 180mg administered by subcutaneous (SC) injection in Induction 2.
Drug: risankizumab SC
Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 360mg administered by subcutaneous (SC) injection in Induction 2.
Drug: risankizumab SC
Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 1800mg administered by intravenous (IV) infusion in Induction 2.
Drug: risankizumab IV
Participants who received placebo with inadequate response in Induction 1 receive risankizumab 1800mg administered by intravenous (IV) infusion in Induction 2.
Drug: risankizumab IV
Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
Drug: placebo for risankizumab
Participants randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion.
Drug: risankizumab IV
Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 180mg administered by subcutaneous (SC) injection in Induction 2.
Drug: risankizumab SC
Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 360mg administered by subcutaneous (SC) injection in Induction 2.
Drug: risankizumab SC
Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion in Induction 2.
Drug: risankizumab IV
Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion in Induction 2.
Drug: risankizumab IV
risankizumab intravenous (IV) infusion
Also known as: ABBV-066, BI 655066
placebo for risankizumab
risankizumab subcutaneous (SC) injection
Also known as: ABBV-066, BI 655066
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 1, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1.
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 2, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1. Evidence of friability during endoscopy in subjects with otherwise "mild" endoscopic activity will confer an endoscopic subscore of 2.
Time frame: Week 12
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement
Endoscopic improvement is defined as endoscopy subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: Week 12
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Full Mayo Score in Participants With a Full Mayo Score of 6 to 12 at Baseline
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Time frame: Week 12
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response per Adapted Mayo Score was defined as decrease from baseline in Adapted Mayo Score ≥ 2 points and ≥ 30%, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
Time frame: Week 12
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score
Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score \>= 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
Time frame: Week 4
Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission
Endoscopic remission was defined as endoscopy subscore of 0.
Time frame: Week 12
Sub-Study 1: Percentage of Participants With Hospitalization
Participants with an event that results in admission to the hospital.
Time frame: Through Week 12
Sub-Study 1: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR)
Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: Week 12
Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)
The US-SQ is a patient questionnaire to assess severity of Ulcerative Colitis (UC) related gastrointestinal symptoms (e.g., frequent bowel movements, abdominal pain, cramping) and non-gastrointestinal symptoms (e.g., joint pain and sleep difficulties). It consists of 17 questions and each question is answered on a scale from can be answered on a scale from 1 (Not at all/ never) to 5 (Very much/Always) with overall symptom score range from 17 to 85. A lower score indicates lower UC severity.
Time frame: Baseline Through Week 12
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)
The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.
Time frame: Baseline Through Week 12
Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Physical Component
The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
Time frame: Baseline Through Week 12
Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Mental Component
The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
Time frame: Baseline through Week 12
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
Time frame: Baseline Through Week 12
Sub-Study 1: Percentage of Participants Undergoing Ulcerative Colitis (UC)-Related Surgeries
Participants who underwent surgery related to UC.
Time frame: Through Week 12
Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical Response is defined as a decrease from baseline in the Adapted Mayo Score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving Endoscopic Improvement
Endoscopic Improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement (HEMI)
Histologic-Endoscopic Mucosal Improvement is defined as an endoscopic subscore of 0 or 1 without evidence of friability and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving Endoscopic Remission
Endoscopic remission per endoscopy subscore. Endoscopic Remission: endoscopic subscore = 0.
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score at Week 4
Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical Response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo Score ≥ 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
Time frame: Week 4
Sub-Study 2: Percentage of Participants Achieving No Bowel Urgency
Percentage of participants who reported no bowel urgency. Bowel urgency was assessed by participants in a subject diary completed once a day.
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving No Abdominal Pain
Percentage of participants who reported no abdominal pain. Abdominal pain was assessed by participants in a subject diary completed once a day.
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR): Endoscopy Subscore of 0 and Geboes Score < 2.0) at Week 12
Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: Week 12
Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
Time frame: Baseline to Week 12
Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.
Time frame: Baseline to Week 12
Sub-Study 2: Occurrence of UC-related Hospitalizations
Participants with an UC-related event that results in admission to the hospital.
Time frame: Baseline Through Week 12
Sub-Study 2: Percentage of Participants Achieving No Nocturnal Bowel Movements
Percentage of participants who reported no nocturnal bowel movements.
Time frame: Week 12
Sub-Study 2: Percentage of Participants Achieving No Tenesmus
Percentage of participants who reported no tenesmus.
Time frame: Week 12
Sub-Study 2: Change in Number of Fecal Incontinence Episodes Per Week
Change in number of fecal incontinence episodes per week.
Time frame: Baseline to Week 12
Sub-Study 2: Change in Number of Days Per Week With Sleep Interrupted Due to UC Symptoms
Change from baseline in number of days per week with sleep interrupted due to UC symptoms.
Time frame: Baseline to Week 12
| Milestone | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 60 | 61 | 61 | 58 | 341 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 53 | 55 | 58 | 57 | 306 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 6 | 3 | 1 | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 2 | 2 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 1 | 2 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 | 0 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 72 | 70 | 36 | 37 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 65 | 57 | 34 | 35 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 7 | 13 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 325 | 652 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 297 | 637 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28 | 15 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 infection | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 71 | 68 | 174 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 65 | 65 | 61 | 164 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 7 | 10 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 4 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Enrolled but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 1, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1.
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score | 1 | 7 | 6 | 6 | 42 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 2, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1. Evidence of friability during endoscopy in subjects with otherwise "mild" endoscopic activity will confer an endoscopic subscore of 2.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score | 6.2 (3.6 to 8.9) | 20.3 (17.2 to 23.4) |
Endoscopic improvement is defined as endoscopy subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement | 3 | 15 | 8 | 9 | 61 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
No measurements were reported for this outcome.
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response per Adapted Mayo Score was defined as decrease from baseline in Adapted Mayo Score ≥ 2 points and ≥ 30%, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score | 12 | 26 | 28 | 31 | 157 |
Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score \>= 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score | 15 | 20 | 28 | 22 | 148 |
Endoscopic remission was defined as endoscopy subscore of 0.
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission | 0 | 5 | 3 | 5 | 22 |
Participants with an event that results in admission to the hospital.
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants With Hospitalization | 5 | 6 | 4 | 3 | 19 |
Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR) | 0 | 3 | 2 | 1 | 10 |
The US-SQ is a patient questionnaire to assess severity of Ulcerative Colitis (UC) related gastrointestinal symptoms (e.g., frequent bowel movements, abdominal pain, cramping) and non-gastrointestinal symptoms (e.g., joint pain and sleep difficulties). It consists of 17 questions and each question is answered on a scale from can be answered on a scale from 1 (Not at all/ never) to 5 (Very much/Always) with overall symptom score range from 17 to 85. A lower score indicates lower UC severity.
| units on a scale | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ) | -7.4 ± 1.53 | -13.8 ± 1.50 | -15.6 ± 1.46 | -15.1 ± 1.51 | -17.1 ± 0.58 |
The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.
| units on a scale | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) | 20.1 ± 4.67 | 37.4 ± 4.56 | 40.3 ± 4.38 | 40.0 ± 4.55 | 49.5 ± 1.86 |
The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
| units on a scale | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Physical Component | 3.904 ± 0.8907 | 5.112 ± 0.8751 | 6.350 ± 0.8341 | 6.296 ± 0.8675 | 7.719 ± 0.3929 |
The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
| unites on a scale | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Mental Component | 3.094 ± 1.2533 | 6.756 ± 1.2319 | 7.284 ± 1.1739 | 5.442 ± 1.2185 | 7.777 ± 0.4777 |
The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
| units on a scale | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) | 3.7 ± 1.37 | 7.6 ± 1.35 | 9.0 ± 1.29 | 8.3 ± 1.33 | 10.7 ± 0.54 |
Participants who underwent surgery related to UC.
| Participants | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV |
|---|---|---|---|---|---|
| Sub-Study 1: Percentage of Participants Undergoing Ulcerative Colitis (UC)-Related Surgeries | 0 | 1 | 0 | 0 | 7 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical Response is defined as a decrease from baseline in the Adapted Mayo Score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score | 35.7 (30.5 to 40.9) | 64.3 (60.6 to 67.9) |
Endoscopic Improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving Endoscopic Improvement | 12.1 (8.5 to 15.6) | 36.5 (32.8 to 40.2) |
Histologic-Endoscopic Mucosal Improvement is defined as an endoscopic subscore of 0 or 1 without evidence of friability and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement (HEMI) | 7.7 (4.8 to 10.6) | 24.5 (21.2 to 27.8) |
Endoscopic remission per endoscopy subscore. Endoscopic Remission: endoscopic subscore = 0.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving Endoscopic Remission | 3.4 (1.4 to 5.4) | 10.6 (8.2 to 13.0) |
Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical Response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo Score ≥ 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score at Week 4 | 30.5 (25.5 to 35.5) | 52.2 (48.3 to 56.0) |
Percentage of participants who reported no bowel urgency. Bowel urgency was assessed by participants in a subject diary completed once a day.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving No Bowel Urgency | 27.7 (22.8 to 32.6) | 44.1 (40.3 to 47.9) |
Percentage of participants who reported no abdominal pain. Abdominal pain was assessed by participants in a subject diary completed once a day.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving No Abdominal Pain | 26.5 (21.7 to 31.3) | 35.8 (32.1 to 39.4) |
Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR): Endoscopy Subscore of 0 and Geboes Score < 2.0) at Week 12 | 0.6 (0.0 to 1.5) | 6.3 (4.4 to 8.2) |
The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
| units on a scale | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) | 3.3 (2.12 to 4.50) | 7.9 (7.03 to 8.69) |
The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.
| units on a scale | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score | 24.3 (20.19 to 28.46) | 42.6 (39.72 to 45.57) |
Participants with an UC-related event that results in admission to the hospital.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Occurrence of UC-related Hospitalizations | 5.5 (3.1 to 8.0) | 0.8 (0.1 to 1.4) |
Percentage of participants who reported no nocturnal bowel movements.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving No Nocturnal Bowel Movements | 43.1 (37.7 to 48.5) | 67.3 (63.7 to 70.9) |
Percentage of participants who reported no tenesmus.
| percentage of participants | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Percentage of Participants Achieving No Tenesmus | 30.2 (25.2 to 35.1) | 48.7 (44.9 to 52.6) |
Change in number of fecal incontinence episodes per week.
| Fecal Incontinence Episodes/ week | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Change in Number of Fecal Incontinence Episodes Per Week | -2.213 (-2.8526 to -1.5726) | -3.839 (-4.2687 to -3.4099) |
Change from baseline in number of days per week with sleep interrupted due to UC symptoms.
| days | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV |
|---|---|---|
| Sub-Study 2: Change in Number of Days Per Week With Sleep Interrupted Due to UC Symptoms | -1.505 (-1.7969 to -1.2122) | -2.485 (-2.6872 to -2.2831) |
Collected over In S1P1, median time on follow-up was 86, 86, 85, 87, & 87 days(d) for S1P1 DB-PboIV, S1P1 DB-Risankizumab(Risa) 600mgIV, S1P1 DB-Risa 1200mgIV, S1P1 DB-Risa 1800mgIV, and S1P1 OL-Risa 1800mgIV; respectively. In S1P2, median time on follow-up was 87, 106, 93 and 93 d for arms S1P2 DB -Risa 1800mgIVPbo, S1P2 DB-Risa1800mgIV, S1P2 DB-Risa 180mgSC, and S1P2 DB-Risa 360mgSC; respectively. In S2P1, median time on follow-up was 87 and 89d for arms S2P1 DB-PboIV, S2P1 DB Risa1200mgIV, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Substudy 1, Induction Period 1: Double-blind Placebo IV | 0/59 (0%) | 6/59 (10.2%) | 14/59 (23.7%) |
| Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | 0/62 (0%) | 6/62 (9.7%) | 13/62 (21%) |
| Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | 0/61 (0%) | 4/61 (6.6%) | 12/61 (19.7%) |
| Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | 0/58 (0%) | 5/58 (8.6%) | 12/58 (20.7%) |
| Substudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IV | 0/341 (0%) | 25/341 (7.3%) | 76/341 (22.3%) |
| Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | 0/36 (0%) | 3/36 (8.3%) | 11/36 (30.6%) |
| Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | 0/37 (0%) | 1/37 (2.7%) | 6/37 (16.2%) |
| Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | 0/71 (0%) | 6/71 (8.5%) | 4/71 (5.6%) |
| Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | 0/71 (0%) | 7/71 (9.9%) | 16/71 (22.5%) |
| Substudy 2, Induction Period 1: Double-blind Placebo IV | 0/324 (0%) | 34/324 (10.5%) | 64/324 (19.8%) |
| Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | 1/653 (0.2%) | 17/653 (2.6%) | 101/653 (15.5%) |
| Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo | 0/174 (0%) | 4/174 (2.3%) | 23/174 (13.2%) |
| Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | 0/68 (0%) | 1/68 (1.5%) | 9/68 (13.2%) |
| Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | 0/71 (0%) | 4/71 (5.6%) | 10/71 (14.1%) |
| Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC | 0/71 (0%) | 1/71 (1.4%) | 23/71 (32.4%) |
| Event | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 3/59 | 1/62 | 0/61 | 0/58 | 16/341 | 1/36 | 0/37 | 3/71 | 2/71 | 16/324 | 3/653 | 1/174 | 0/68 | 1/71 | 1/71 |
| ANAEMIABlood and lymphatic system disorders | 0/59 | 0/62 | 2/61 | 0/58 | 0/341 | 0/36 | 0/37 | 0/71 | 1/71 | 2/324 | 2/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| ERYSIPELASInfections and infestations | 0/59 | 0/62 | 0/61 | 0/58 | 0/341 | 1/36 | 0/37 | 0/71 | 0/71 | 0/324 | 0/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| LUNG ABSCESSInfections and infestations | 0/59 | 0/62 | 0/61 | 0/58 | 0/341 | 1/36 | 0/37 | 0/71 | 0/71 | 0/324 | 0/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| OSTEONECROSISMusculoskeletal and connective tissue disorders | 1/59 | 0/62 | 0/61 | 0/58 | 0/341 | 1/36 | 0/37 | 0/71 | 0/71 | 0/324 | 1/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| PEMPHIGOIDSkin and subcutaneous tissue disorders | 0/59 | 0/62 | 0/61 | 0/58 | 0/341 | 1/36 | 0/37 | 0/71 | 0/71 | 0/324 | 0/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| SALMONELLOSISInfections and infestations | 0/59 | 0/62 | 0/61 | 0/58 | 0/341 | 0/36 | 1/37 | 0/71 | 0/71 | 0/324 | 0/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| BLOOD LOSS ANAEMIABlood and lymphatic system disorders | 0/59 | 0/62 | 0/61 | 1/58 | 0/341 | 0/36 | 0/37 | 0/71 | 0/71 | 0/324 | 0/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| COLITISGastrointestinal disorders | 0/59 | 1/62 | 0/61 | 1/58 | 0/341 | 0/36 | 0/37 | 0/71 | 0/71 | 0/324 | 0/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| APPENDICITISInfections and infestations | 0/59 | 0/62 | 0/61 | 1/58 | 0/341 | 0/36 | 0/37 | 0/71 | 0/71 | 1/324 | 0/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| Event | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 4/59 | 5/62 | 3/61 | 5/58 | 24/341 | 2/36 | 4/37 | 1/71 | 6/71 | 8/324 | 18/653 | 3/174 | 0/68 | 1/71 | 4/71 |
| COLITIS ULCERATIVEGastrointestinal disorders | 5/59 | 1/62 | 3/61 | 1/58 | 12/341 | 1/36 | 1/37 | 0/71 | 3/71 | 17/324 | 10/653 | 3/174 | 1/68 | 3/71 | 0/71 |
| ANAEMIABlood and lymphatic system disorders | 2/59 | 0/62 | 2/61 | 1/58 | 12/341 | 0/36 | 1/37 | 1/71 | 1/71 | 19/324 | 21/653 | 5/174 | 1/68 | 2/71 | 6/71 |
| COVID-19Infections and infestations | 0/59 | 0/62 | 0/61 | 0/58 | 1/341 | 0/36 | 0/37 | 0/71 | 0/71 | 19/324 | 30/653 | 10/174 | 4/68 | 4/71 | 6/71 |
| HEADACHENervous system disorders | 3/59 | 2/62 | 3/61 | 4/58 | 22/341 | 2/36 | 0/37 | 2/71 | 5/71 | 7/324 | 19/653 | 3/174 | 2/68 | 1/71 | 6/71 |
| BRONCHITISInfections and infestations | 0/59 | 4/62 | 1/61 | 0/58 | 1/341 | 0/36 | 0/37 | 0/71 | 0/71 | 0/324 | 2/653 | 1/174 | 1/68 | 0/71 | 1/71 |
| PHARYNGITISInfections and infestations | 1/59 | 1/62 | 0/61 | 0/58 | 3/341 | 2/36 | 0/37 | 0/71 | 1/71 | 0/324 | 0/653 | 1/174 | 0/68 | 0/71 | 0/71 |
| SINUSITISInfections and infestations | 0/59 | 0/62 | 1/61 | 1/58 | 3/341 | 2/36 | 0/37 | 0/71 | 2/71 | 1/324 | 1/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| DRY SKINSkin and subcutaneous tissue disorders | 0/59 | 2/62 | 0/61 | 0/58 | 4/341 | 2/36 | 0/37 | 0/71 | 1/71 | 2/324 | 3/653 | 0/174 | 0/68 | 0/71 | 0/71 |
| HAEMORRHOIDSGastrointestinal disorders | 3/59 | 0/62 | 0/61 | 0/58 | 0/341 | 1/36 | 0/37 | 0/71 | 1/71 | 0/324 | 5/653 | 0/174 | 0/68 | 1/71 | 1/71 |
Includes all enrolled subjects that received at least one dose of study drug.
| Age, Continuous(years) | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Substudy 1 | 44.4 ± 14.09 | 43.0 ± 14.90 | 41.8 ± 13.80 | 40.9 ± 13.73 | 40.4 ± 14.17 | — | — | 42.5 ± 14.12 |
| Substudy 2 | — | — | — | — | — | 42.8 ± 14.30 | 41.8 ± 13.47 | 42.1 ± 13.75 |
| Age, Customized(Participants) | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Age Group — 18 - <40 | 25 | 27 | 30 | 33 | 175 | 147 | 313 | 750 |
| Age Group — 40 - <65 | 29 | 27 | 27 | 20 | 143 | 153 | 299 | 698 |
| Age Group — ≥65 | 6 | 7 | 4 | 5 | 22 | 25 | 38 | 107 |
| Sex: Female, Male(Participants) | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 24 | 21 | 26 | 27 | 145 | 124 | 265 | 632 |
| Male | 36 | 40 | 35 | 31 | 195 | 201 | 385 | 923 |
| Ethnicity (NIH/OMB)(Participants) | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 6 | 1 | 21 | 20 | 44 | 97 |
| Not Hispanic or Latino | 57 | 59 | 55 | 57 | 319 | 305 | 606 | 1458 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 14 | 11 | 15 | 11 | 47 | 96 | 171 | 365 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 1 | 2 | 3 | 7 | 12 | 28 |
| White | 44 | 49 | 45 | 45 | 290 | 218 | 461 | 1152 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 4 | 5 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adapted Mayo Score(Adapted Mayo Score 0 - 9) | Substudy 1, Induction Period 1: Double-blind Placebo IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | Substudy 2, Induction Period 1: Double-blind Placebo IV | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Substudy 1 - ITT1A Population | 7.012 ± 1.1645 | 6.929 ± 1.2240 | 7.011 ± 1.1288 | 7.150 ± 1.3908 | — | — | — | 7.024 ± 1.2240 |
| Substudy 1 - ITT1B Population | — | — | — | — | 7.179 ± 1.2279 | — | — | 7.179 ± 1.2279 |
| Substudy 2 - ITT2 Population | — | — | — | — | — | 7.052 ± 1.2800 | 7.068 ± 1.2173 | 7.063 ± 1.2380 |
Showing the first 100 of 430 sites across 44 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Mar 2018 to primary completion in Nov 2022, 56 months.
Results were first posted in Jan 2025, 2 years 2 months after primary completion. A results delay was requested in Jul 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab